Article - 03/05/2008 Immatics started second proof-of-concept study Immatics biotechnologies GmbH announced the start of a Phase III trial of its IMA910 cancer vaccine in patients with advanced colorectal cancer. The study will enroll about 70 patients in 8 European countries. The vaccine is developed to slow or halt tumor progression.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-started-second-proof-of-concept-study
Article - 01/05/2008 Peter Öhlschläger - New strategies for the treatment of cancer Professor Peter Öhlschläger established his major scientific interests very early on. During his degree thesis at the German Cancer Research Centre DKFZ in Heidelberg the immunologist succeeded in combining his two major interests namely virology and cancer. Öhlschläger is now junior professor at the University of Constance and mainly deals with the development of therapeutic cancer vaccines. https://www.gesundheitsindustrie-bw.de/en/article/news/peter-hlschlaeger-new-strategies-for-the-treatment-of-cancer
Article - 26/04/2008 Fight against fire blight Burst bark mucus secretions blackened leaves crop failures - these all represent huge ecological and economic damage and are known as fire blight. Fire blight is an example of how global trade and traffic leads to the spread of a pathogen across almost the entire world.https://www.gesundheitsindustrie-bw.de/en/article/news/fight-against-fire-blight
Press release - 16/04/2008 Effective Cancer Immune Therapy Through Order in the Blood Vessels Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
Article - 01/03/2008 New active substance against hepatitis B Scientists at the University Hospital in Heidelberg have discovered a hepatitis B virus peptide that can prevent viral infections in a mouse model. A team led by Professor Stephan Urban is developing a virus blocker against hepatitis B infections. Despite vaccinations every year about 750000 people die from the consequences of hepatitis B infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-active-substance-against-hepatitis-b
Article - 12/02/2008 Hermann Bujard - a passionate basic researcher As one of the people who initiated the establishment of EMBL and in his role as founding director of the ZMBH Hermann Bujard has made a considerable contribution to the transformation of Heidelberg into a leading location for molecular and biological research in Germany. As the director of EMBO Bujard is now promoting the development of molecular biosciences across Europe.https://www.gesundheitsindustrie-bw.de/en/article/news/hermann-bujard-a-passionate-basic-researcher
Article - 08/02/2008 Nycomed and Wyeth announce launch of an own generic version of PROTONIX® – lawsuit to defend patent continues Nycomed and its licence holder Wyeth Pharmaceuticals a division of Wyeth NYSEWYE today announced the U.S. launch of an own generic version of PROTONIX Pantoprazole tablets in response to the at-risk launch of generic Pantoprazole tablets by Teva Pharmaceuticals USA Inc.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-wyeth-announce-launch-of-an-own-generic-version-of-protonix-lawsuit-to-defend-patent-con
Article - 12/01/2008 Peptide chips for improved cancer diagnostics Scientists at the German Cancer Research Centre DKFZ have now succeeded in generating peptides on a microchip - faster and thus cheaper than with previous methods.https://www.gesundheitsindustrie-bw.de/en/article/news/peptide-chips-for-improved-cancer-diagnostics